Related references
Note: Only part of the references are listed.Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes
Aline H. de Nooijer et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Luca Perico et al.
NATURE REVIEWS NEPHROLOGY (2021)
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Yajing Fu et al.
VIROLOGICA SINICA (2020)
Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?
Courtney M. Campbell et al.
CIRCULATION (2020)
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases
Cynthia Magro et al.
TRANSLATIONAL RESEARCH (2020)
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Christopher M. Petrilli et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism
Joris R. Delanghe et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
Sara Mastaglio et al.
CLINICAL IMMUNOLOGY (2020)
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
Dennis McGonagle et al.
AUTOIMMUNITY REVIEWS (2020)
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
Alessandro Rambaldi et al.
IMMUNOBIOLOGY (2020)
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
Valentina Giudice et al.
FRONTIERS IN PHARMACOLOGY (2020)
Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases
Bobek Ilona et al.
ORVOSI HETILAP (2020)
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition
Jia Yu et al.
BLOOD (2020)
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection
Vijendra Ramlall et al.
NATURE MEDICINE (2020)
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
Jeffrey Laurence et al.
CLINICAL IMMUNOLOGY (2020)
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
Keisha Smith et al.
TRIALS (2020)
Eculizumab treatment for renal failure in a pediatric patient with COVID-19
Ruchi Mahajan et al.
JOURNAL OF NEPHROLOGY (2020)
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Jan C. Holter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients
Oskar Eriksson et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System
Pascal Urwyler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study
Shilin Fang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Alexander P. J. Vlaar et al.
LANCET RHEUMATOLOGY (2020)
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study
Djillali Annane et al.
ECLINICALMEDICINE (2020)
Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression
Maria Prendecki et al.
CLINICAL KIDNEY JOURNAL (2020)
Complement analysis in the era of targeted therapeutics
Zoltan Prohaszka et al.
MOLECULAR IMMUNOLOGY (2018)
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Lisa E. Gralinski et al.
MBIO (2018)
Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control
Zoltan Prohaszka et al.
IMMUNOBIOLOGY (2016)
Complement system part II: role in immunity
Nicolas S. Merle et al.
FRONTIERS IN IMMUNOLOGY (2015)
Complement system part I - molecular mechanisms of activation and regulation
Nicolas S. Merle et al.
FRONTIERS IN IMMUNOLOGY (2015)
Complement activation in thrombotic thrombocytopenic purpura
M. Reti et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Ali Moh Zaki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk
Meike Heurich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Traitors of the immune system-enhancing antibodies in HIV infection:: Their possible implication in HIV vaccine development
Zoltan Beck et al.
VACCINE (2008)
Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART)
D Bánhegyi et al.
IMMUNOLOGY LETTERS (2003)
'Complementing' viral infection: mechanisms for evading innate immunity
SH Lee et al.
TRENDS IN MICROBIOLOGY (2003)
Characterization of a novel coronavirus associated with severe acute respiratory syndrome
PA Rota et al.
SCIENCE (2003)
A major outbreak of severe acute respiratory syndrome in Hong Kong
N Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Coronavirus as a possible cause of severe acute respiratory syndrome
JSM Peiris et al.
LANCET (2003)
Advances in immunology: Complement (First of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
